Published in Proc Natl Acad Sci U S A on September 03, 2010
Small molecule inhibitors reveal Niemann-Pick C1 is essential for Ebola virus infection. Nature (2011) 3.66
Ebola virus entry requires the host-programmed recognition of an intracellular receptor. EMBO J (2012) 2.08
FDA-approved selective estrogen receptor modulators inhibit Ebola virus infection. Sci Transl Med (2013) 1.62
Filoviruses require endosomal cysteine proteases for entry but exhibit distinct protease preferences. J Virol (2012) 1.21
Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs. Emerg Microbes Infect (2014) 1.18
Filovirus entry into cells - new insights. Curr Opin Virol (2012) 1.14
African swine fever virus uses macropinocytosis to enter host cells. PLoS Pathog (2012) 1.10
Human metapneumovirus (HMPV) binding and infection are mediated by interactions between the HMPV fusion protein and heparan sulfate. J Virol (2012) 1.08
A new player in the puzzle of filovirus entry. Nat Rev Microbiol (2012) 1.08
Shed GP of Ebola virus triggers immune activation and increased vascular permeability. PLoS Pathog (2014) 1.06
Virtual screen for repurposing approved and experimental drugs for candidate inhibitors of EBOLA virus infection. F1000Res (2015) 0.94
The role of antigen-presenting cells in filoviral hemorrhagic fever: gaps in current knowledge. Antiviral Res (2012) 0.92
Ebola virus exploits a monocyte differentiation program to promote its entry. J Virol (2013) 0.86
Lectin-dependent enhancement of Ebola virus infection via soluble and transmembrane C-type lectin receptors. PLoS One (2013) 0.81
The Tetherin Antagonism of the Ebola Virus Glycoprotein Requires an Intact Receptor-Binding Domain and Can Be Blocked by GP1-Specific Antibodies. J Virol (2016) 0.76
Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection. Science (2005) 7.07
A system for functional analysis of Ebola virus glycoprotein. Proc Natl Acad Sci U S A (1997) 6.86
Characterization of Ebola virus entry by using pseudotyped viruses: identification of receptor-deficient cell lines. J Virol (1998) 5.16
Kinetic analysis of secretory protein traffic and characterization of golgi to plasma membrane transport intermediates in living cells. J Cell Biol (1998) 5.14
Role of endosomal cathepsins in entry mediated by the Ebola virus glycoprotein. J Virol (2006) 4.24
Intracellular signalling controlling integrin activation in lymphocytes. Nat Rev Immunol (2005) 3.54
Ebola virus VP40-induced particle formation and association with the lipid bilayer. J Virol (2001) 3.41
Dual-color visualization of trans-Golgi network to plasma membrane traffic along microtubules in living cells. J Cell Sci (1999) 3.26
Contribution of ebola virus glycoprotein, nucleoprotein, and VP24 to budding of VP40 virus-like particles. J Virol (2004) 2.92
Pathogenesis of Ebola hemorrhagic fever in primate models: evidence that hemorrhage is not a direct effect of virus-induced cytolysis of endothelial cells. Am J Pathol (2003) 2.66
Conserved receptor-binding domains of Lake Victoria marburgvirus and Zaire ebolavirus bind a common receptor. J Biol Chem (2006) 2.56
Apoptosis induced in vitro and in vivo during infection by Ebola and Marburg viruses. Lab Invest (2000) 2.45
Arf6 and microtubules in adhesion-dependent trafficking of lipid rafts. Nat Cell Biol (2007) 2.23
Proteolysis of the Ebola virus glycoproteins enhances virus binding and infectivity. J Virol (2007) 2.16
The primed ebolavirus glycoprotein (19-kilodalton GP1,2): sequence and residues critical for host cell binding. J Virol (2009) 2.15
Proinflammatory response during Ebola virus infection of primate models: possible involvement of the tumor necrosis factor receptor superfamily. Immunol Lett (2002) 2.06
Infection and activation of monocytes by Marburg and Ebola viruses. J Virol (2001) 1.90
Cell adhesion molecules and actin cytoskeleton at immune synapses and kinapses. Curr Opin Cell Biol (2007) 1.68
Ebolavirus glycoprotein structure and mechanism of entry. Future Virol (2009) 1.56
Depletion of peripheral blood T lymphocytes and NK cells during the course of ebola hemorrhagic Fever in cynomolgus macaques. Viral Immunol (2004) 1.55
An enzymatic virus-like particle assay for sensitive detection of virus entry. J Virol Methods (2009) 1.42
Implication of a retrovirus-like glycoprotein peptide in the immunopathogenesis of Ebola and Marburg viruses. FASEB J (2006) 1.28
Alpha5beta1-integrin controls ebolavirus entry by regulating endosomal cathepsins. Proc Natl Acad Sci U S A (2009) 1.26
Analysis of the co-localization of the insulin-responsive glucose transporter (GLUT4) and the trans Golgi network marker TGN38 within 3T3-L1 adipocytes. Biochem J (1994) 1.17
Recycling of AQP2 occurs through a temperature- and bafilomycin-sensitive trans-Golgi-associated compartment. Am J Physiol Renal Physiol (2000) 1.13
Membrane topology of the mammalian CMP-sialic acid transporter. J Biol Chem (1999) 1.10
Cell adhesion promotes Ebola virus envelope glycoprotein-mediated binding and infection. J Virol (2008) 1.05
Digitonin permeabilization procedures for the study of endosome acidification and function. Methods Cell Biol (1989) 1.05
Expression of Ebolavirus glycoprotein on the target cells enhances viral entry. Virol J (2009) 1.04
Structures and mechanisms of viral membrane fusion proteins: multiple variations on a common theme. Crit Rev Biochem Mol Biol (2008) 5.26
Influenza virus pleiomorphy characterized by cryoelectron tomography. Proc Natl Acad Sci U S A (2006) 3.25
Ephrin-B2 ligand is a functional receptor for Hendra virus and Nipah virus. Proc Natl Acad Sci U S A (2005) 3.18
Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes. Proc Natl Acad Sci U S A (2002) 3.08
Hendra and Nipah viruses: different and dangerous. Nat Rev Microbiol (2006) 2.95
Overlooking subvisible particles in therapeutic protein products: gaps that may compromise product quality. J Pharm Sci (2009) 2.36
Comparative analysis of bat genomes provides insight into the evolution of flight and immunity. Science (2012) 2.29
The primed ebolavirus glycoprotein (19-kilodalton GP1,2): sequence and residues critical for host cell binding. J Virol (2009) 2.15
A neutralizing human monoclonal antibody protects against lethal disease in a new ferret model of acute nipah virus infection. PLoS Pathog (2009) 2.09
Host cell recognition by the henipaviruses: crystal structures of the Nipah G attachment glycoprotein and its complex with ephrin-B3. Proc Natl Acad Sci U S A (2008) 2.08
Thiol/disulfide exchange is a prerequisite for CXCR4-tropic HIV-1 envelope-mediated T-cell fusion during viral entry. Blood (2003) 2.00
Potent neutralization of Hendra and Nipah viruses by human monoclonal antibodies. J Virol (2006) 2.00
Receptor binding, fusion inhibition, and induction of cross-reactive neutralizing antibodies by a soluble G glycoprotein of Hendra virus. J Virol (2005) 1.89
Broadly cross-reactive HIV neutralizing human monoclonal antibody Fab selected by sequential antigen panning of a phage display library. J Immunol Methods (2003) 1.87
Feline model of acute nipah virus infection and protection with a soluble glycoprotein-based subunit vaccine. J Virol (2006) 1.87
Identification and characterization of a new cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody. J Virol (2004) 1.80
Membrane fusion tropism and heterotypic functional activities of the Nipah virus and Hendra virus envelope glycoproteins. J Virol (2002) 1.69
Vertical transmission and fetal replication of Nipah virus in an experimentally infected cat. J Infect Dis (2007) 1.68
The avian retrovirus avian sarcoma/leukosis virus subtype A reaches the lipid mixing stage of fusion at neutral pH. J Virol (2003) 1.63
Sequential roles of receptor binding and low pH in forming prehairpin and hairpin conformations of a retroviral envelope glycoprotein. J Virol (2004) 1.62
FDA-approved selective estrogen receptor modulators inhibit Ebola virus infection. Sci Transl Med (2013) 1.62
Identification of Hendra virus G glycoprotein residues that are critical for receptor binding. J Virol (2007) 1.61
Development of an acute and highly pathogenic nonhuman primate model of Nipah virus infection. PLoS One (2010) 1.54
Inhibitors of protein-disulfide isomerase prevent cleavage of disulfide bonds in receptor-bound glycoprotein 120 and prevent HIV-1 entry. J Biol Chem (2002) 1.54
Antibodies to Nipah or Nipah-like viruses in bats, China. Emerg Infect Dis (2008) 1.53
Fusion peptide of influenza hemagglutinin requires a fixed angle boomerang structure for activity. J Biol Chem (2005) 1.51
Extensively cross-reactive anti-HIV-1 neutralizing antibodies induced by gp140 immunization. Proc Natl Acad Sci U S A (2007) 1.50
Exceptionally potent cross-reactive neutralization of Nipah and Hendra viruses by a human monoclonal antibody. J Infect Dis (2008) 1.48
Cathepsin cleavage potentiates the Ebola virus glycoprotein to undergo a subsequent fusion-relevant conformational change. J Virol (2011) 1.46
Heptad repeat 2-based peptides inhibit avian sarcoma and leukosis virus subgroup a infection and identify a fusion intermediate. J Virol (2004) 1.44
A recombinant subunit vaccine formulation protects against lethal Nipah virus challenge in cats. Vaccine (2008) 1.41
Residues in the stalk domain of the hendra virus g glycoprotein modulate conformational changes associated with receptor binding. J Virol (2008) 1.40
A recombinant Hendra virus G glycoprotein-based subunit vaccine protects ferrets from lethal Hendra virus challenge. Vaccine (2011) 1.39
Leash in the groove mechanism of membrane fusion. Nat Struct Biol (2003) 1.36
A neutralizing human monoclonal antibody protects african green monkeys from hendra virus challenge. Sci Transl Med (2011) 1.35
Quantitative analysis of Nipah virus proteins released as virus-like particles reveals central role for the matrix protein. Virol J (2007) 1.30
Multiple cationic amphiphiles induce a Niemann-Pick C phenotype and inhibit Ebola virus entry and infection. PLoS One (2013) 1.29
Alpha5beta1-integrin controls ebolavirus entry by regulating endosomal cathepsins. Proc Natl Acad Sci U S A (2009) 1.26
A novel model of lethal Hendra virus infection in African green monkeys and the effectiveness of ribavirin treatment. J Virol (2010) 1.21
Inhibition of Henipavirus fusion and infection by heptad-derived peptides of the Nipah virus fusion glycoprotein. Virol J (2005) 1.21
Functional studies of host-specific ephrin-B ligands as Henipavirus receptors. Virology (2007) 1.21
Structure and function of the complete internal fusion loop from Ebolavirus glycoprotein 2. Proc Natl Acad Sci U S A (2011) 1.20
Selective modulation of integrin-mediated cell migration by distinct ADAM family members. Mol Biol Cell (2005) 1.20
A Hendra virus G glycoprotein subunit vaccine protects African green monkeys from Nipah virus challenge. Sci Transl Med (2012) 1.20
Selection of a novel gp41-specific HIV-1 neutralizing human antibody by competitive antigen panning. J Immunol Methods (2006) 1.19
Anti-gp41 antibodies cloned from HIV-infected patients with broadly neutralizing serologic activity. J Virol (2010) 1.17
Hendra virus vaccine, a one health approach to protecting horse, human, and environmental health. Emerg Infect Dis (2014) 1.16
Animal challenge models of henipavirus infection and pathogenesis. Curr Top Microbiol Immunol (2012) 1.11
Chloroquine administration does not prevent Nipah virus infection and disease in ferrets. J Virol (2009) 1.09
Considerations for the development of therapeutic monoclonal antibodies. Curr Opin Immunol (2008) 1.09
A new player in the puzzle of filovirus entry. Nat Rev Microbiol (2012) 1.08
Marked structural and functional heterogeneity in CXCR4: separation of HIV-1 and SDF-1alpha responses. Immunol Cell Biol (2005) 1.06
Simian immunodeficiency viruses from multiple lineages infect human macrophages: implications for cross-species transmission. J Acquir Immune Defic Syndr (2003) 1.06
The YPLGVG sequence of the Nipah virus matrix protein is required for budding. Virol J (2008) 1.05
Cell adhesion promotes Ebola virus envelope glycoprotein-mediated binding and infection. J Virol (2008) 1.05
Novel monoclonal antibody directed at the receptor binding site on the avian sarcoma and leukosis virus Env complex. J Virol (2002) 1.02
Antibodies to henipavirus or henipa-like viruses in domestic pigs in Ghana, West Africa. PLoS One (2011) 1.02
Hendra and Nipah viruses: pathogenesis and therapeutics. Curr Mol Med (2005) 1.02
New insights into the spring-loaded conformational change of influenza virus hemagglutinin. J Virol (2002) 1.01
Protection of rhesus monkeys against infection with minimally pathogenic simian-human immunodeficiency virus: correlations with neutralizing antibodies and cytotoxic T cells. J Virol (2005) 1.01
Conserved eukaryotic fusogens can fuse viral envelopes to cells. Science (2011) 1.01
The cysteine-rich domain regulates ADAM protease function in vivo. J Cell Biol (2002) 1.00
Viral glycoprotein-mediated cell fusion assays using vaccinia virus vectors. Methods Mol Biol (2004) 0.99
Cysteines flanking the internal fusion peptide are required for the avian sarcoma/leukosis virus glycoprotein to mediate the lipid mixing stage of fusion with high efficiency. J Virol (2008) 0.99
Henipavirus neutralising antibodies in an isolated island population of African fruit bats. PLoS One (2012) 0.98
Potent human monoclonal antibodies against SARS CoV, Nipah and Hendra viruses. Expert Opin Biol Ther (2009) 0.98
A spatio-temporal analysis of matrix protein and nucleocapsid trafficking during vesicular stomatitis virus uncoating. PLoS Pathog (2010) 0.97
Structural requirements for the inhibitory action of the CD9 large extracellular domain in sperm/oocyte binding and fusion. Biochem Biophys Res Commun (2003) 0.97
Glycoprotein-dependent acidification of vesicular stomatitis virus enhances release of matrix protein. J Virol (2009) 0.97
Mechanisms for macrophage-mediated HIV-1 induction. J Immunol (2004) 0.96
A single glycosylation site within the receptor-binding domain of the avian sarcoma/leukosis virus glycoprotein is critical for receptor binding. Virology (2002) 0.96
Biochemical, conformational, and immunogenic analysis of soluble trimeric forms of henipavirus fusion glycoproteins. J Virol (2012) 0.96
ADAM13 induces cranial neural crest by cleaving class B Ephrins and regulating Wnt signaling. Dev Cell (2010) 0.94
Heme oxygenase-1 induction alters chemokine regulation and ameliorates human immunodeficiency virus-type-1 infection in lipopolysaccharide-stimulated macrophages. Biochem Biophys Res Commun (2013) 0.93